The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Advances in biomarker-driven therapies in pancreatic cancer
Davide Melisi, MD, PhD, University of Verona, Verona, Italy, highlights the importance of developing therapies for pancreatic cancer based on biomarker-selected populations. Pancreatic tumors are heterogenous, and biomarker identification, such as KRAS mutations, can be easily detected with accessible technologies. Novel agents, including monoclonal antibodies targeting claudin 18.2, and therapies for patients with MTAP expression or BRCA1/2 or PALB2 mutations are in development. These biomarkers can be efficiently identified, making targeted therapies more feasible and effective. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
